Heart Failure Awareness Week 2026: Build one accountable system for diagnosis, treatment optimization, transition, and living well with heart failure

Heart Failure Awareness Week is an opportunity to examine whether the organization has designed care around a progressive condition or around departmental boundaries. People may enter through primary care, urgent care, an emergency department, a cardiology clinic, a hospitalization, or a remote alert. They may have reduced, mildly reduced, or preserved ejection fraction, multiple chronic conditions, functional limitations, medication intolerance, transportation barriers, or a caregiver who is already carrying substantial work. A reliable system must recognize these differences while keeping the next decision visible.

The executive question is not whether clinicians know the evidence. It is whether the care delivery system makes evidence-based action easier at the moment it is needed. That requires a defined diagnostic route, prompt classification, medication and nonpharmacologic treatment, laboratory and symptom surveillance, a high-reliability discharge process, early follow-up, rehabilitation and activity support, self-care education, caregiver preparation, and access to supportive or palliative care according to need. Each element can be strong in isolation while patients still experience delay and fragmentation at the interfaces.

Contemporary research shows why implementation deserves the same attention as clinical knowledge. In a 2026 observational comparison, a standardized home titration pathway supported by telemonitoring was associated with a median 48 days to optimal medical therapy, compared with 321 days in a contemporaneous usual-care group [1]. This is not randomized evidence, and the participating population and safety infrastructure matter. It does show how much time can accumulate when every dose change depends on another visit, another message, or another unowned handoff.

A large Australian implementation study used data-supported identification and a nurse-led remote optimization program for 2,004 people with heart failure with reduced ejection fraction. Four-pillar therapy increased from 11.1% before the intervention to 49.8% afterward, and the team documented barriers when therapy remained submaximal [10]. The before-and-after design cannot isolate every cause of change, but it makes a useful operational point: finding eligible patients, assigning a team, acting through protocols, and recording reasons for exceptions create a measurable treatment system.

Diagnosis also has an operating model. A 2026 economic evaluation modeled a digital pathway for suspected heart failure, using faster access to diagnostic information and earlier treatment as the mechanism. The model estimated about 0.056 incremental quality-adjusted life-years and a cost of £5,882 per quality-adjusted life-year [3]. Those values should not be transferred directly to another health system. The study is useful because it connects diagnostic delay to downstream clinical and economic consequences and makes the assumptions visible.

Remote care evidence is promising but not uniform. A 2026 systematic review and meta-analysis of 16 randomized trials reported lower all-cause mortality, all-cause hospitalization, and heart-failure hospitalization with telemedicine strategies, while also finding that effects differed by intervention mechanism [2]. A 2025 systematic review of 32 randomized trials reached a more cautious conclusion: noninvasive telemonitoring produced mixed effects across mortality, readmission, and quality of life, with substantial variation in devices, feedback, clinical review, and patient participation [12]. Leaders should therefore buy a care process, not a device. Monitoring must have a target population, an accountable reviewer, decision thresholds, response times, escalation pathways, and an equity plan.

Disease-management programs offer the broadest frame. A contemporary review describes an integrated model that combines identification and risk stratification, multidisciplinary care, therapy optimization, patient education, transitional follow-up, remote monitoring, performance measurement, and social support [9]. A nurse-coordinated multidisciplinary program evaluated with propensity matching also supports the value of connecting disciplines within one management structure [11]. Neither source provides a universal blueprint. Together, they support a design principle: the patient needs one coherent system with explicit accountability across settings.

Fragmentation often appears as a clinical problem but originates in workflow. An abnormal test may be available but not assigned. A discharge order may list a medication without a laboratory plan. A patient may receive a scale but no monitored channel. A primary care clinician may assume cardiology will titrate, while cardiology assumes the referring team will act. Every queue can look busy while no one owns the next decision.

Medication inertia is similarly multicausal. Clinicians may face limited visit time, uncertain recent laboratory results, unclear titration authority, competing acute concerns, or difficulty reaching the patient. Patients may encounter cost, pharmacy access, adverse effects, misunderstanding, or a regimen that exceeds daily capacity. Standard work should separate clinical reasons, patient preference, access barriers, and process delay. A simple "not on target therapy" measure cannot tell a team what to fix.

Digital programs create another interface. A monitor can detect information but cannot decide who responds, how quickly, or what happens when data stop. The qualitative study of caregivers performing home telemonitoring found that caregiving experience and responsibility shape how monitoring is performed [17]. The evidence base on telemonitoring also shows that intervention components vary widely [2] [12]. Procurement should therefore include clinical workflow, patient and caregiver burden, interoperability, alert governance, after-hours coverage, accessibility, and a plan for nonparticipation.

Equity cannot be inferred from an overall improvement. The 2025 analysis of socio-demographic and ethnic determinants in therapy implementation illustrates why leaders should examine who receives and advances through treatment [7]. Stratification should be selected with patient, community, legal, privacy, and data-governance input. Small numbers require suppression and cautious interpretation. A gap is a signal for investigation, not automatic proof of mechanism.

The most useful equity review connects quantitative and qualitative evidence. If follow-up is slower for a group, teams should examine scheduling rules, geography, transportation, language, digital access, work hours, caregiving demands, trust, medication cost, and the quality of the original handoff. They should also ask patients and staff how the process functions in practice. The goal is not to explain the gap away. It is to identify a changeable barrier and test a response.

Supportive and palliative care can also be lost between services. A formative evaluation of a dyadic intervention found value in bringing self-management, social support, communication about care values, and awareness of palliative care into one design [18]. More recent mixed-methods work found that serious-illness conversations could be worthwhile while still producing ambivalence or distress for some participants [4]. Leaders should avoid both late referral and a scripted conversation that ignores readiness, culture, relationships, or follow-up.

Begin with a diagnostic funnel. Define the population in whom heart failure is suspected, the expected initial evaluation, the time to definitive testing, the time to classification, and the time to a documented plan. Track tests without an owner and referrals that do not reach a decision. If the denominator cannot be defined reliably, leaders should first improve data capture rather than publish a precise rate built on incomplete identification.

The treatment view should show eligibility and clinical exceptions, not simply medication prevalence. For each therapy or treatment domain, report the eligible denominator, initiation, dose or optimization status when clinically meaningful, time to next review, safety monitoring, patient decline, access barrier, and unresolved exception. Registry and implementation studies show why these distinctions matter [1] [6] [10].

The transition view should measure medication reconciliation, patient understanding, access to medicines and equipment, scheduled laboratory testing, early contact, attended follow-up, and closed-loop communication to the receiving team. Readmission is important but is too distal and confounded to diagnose the process by itself. Pair utilization with measures that reveal whether the transition work occurred.

Living-well measures should include symptoms, function, quality of life, confidence, rehabilitation or activity participation, caregiver preparedness when relevant, and the alignment of care with patient goals. Caregiver education, dyadic recognition, and care-dependency studies support assessment of the household care system, while also reminding leaders that families should not become unpaid substitutes for missing professional care [13] [14] [15] [16].

Remote-monitoring measures should include reach, sustained participation, missing-data patterns, alert volume, review timeliness, action rates, false or low-value alerts, patient and caregiver workload, technical support, and outcomes. Report results by access-relevant groups. The mixed telemonitoring literature argues against treating enrollment or device activation as the outcome [2] [12].

Every dashboard should state definitions, time windows, exclusions, data completeness, and small-number rules. A difference between sites or groups is a starting point for review. It is not proof of quality, causation, or inequity without context. The scorecard should connect each signal to an owner, a review rule, and an action.